October 12, 2018
Synspire Pharmaceuticals Announces Abstracts Evaluating New Treatment Options for Cystic Fibrosis Complications Accepted for Presentation at the 32nd Annual North American Cystic Fibrosis Conference
Cambridge, Mass. – October 12, 2018 — Synspire Pharmaceuticals, a privately held company developing a new class of inhaled glycopolymer-based therapeutics for the treatment of pulmonary disease, today announced that three abstracts have been accepted for presentation at the 32ndAnnual North American Cystic Fibrosis Conference (NACFC), occurring October 18-20 in Denver, CO. The three presentations detail the results of research undertaken with polycationic glycopolymer poly (acetyl, arginyl) glucosamine (PAAG) that is being developed by Synspire as SNSP113, an inhaled treatment designed to improve lung function in patients with cystic fibrosis (CF).
Results of all three studies will be presented at Poster Session I.
Presenter: Courtney Fernandez Petty, Ph.D.
Title: PAAG Improves Mucociliary Transport in CF Rats
Date: Thursday, October 18, 2018
Time: 11:15 – 1:45 PM MT
Dr. Fernandez Petty’s presentation will highlight the work led by collaborators Steven Rowe, M.D. and his team at the University of Alabama at Birmingham, and Guillermo Tearney, M.D., Ph.D. at the Tearney Lab in the Wellman Center for Photomedicine, Massachusetts General Hospital, Boston, Massachusetts. The presentation will focus on the beneficial mucoactive effects of PAAG on mucociliary transport in the trachea and lungs of CF rats.
Presenter: Dixon Johns, B.S.
Title: Novel Disruption of an Alginate Biofilm Infection Model of CF Respiratory Disease
Date: Thursday, October 18, 2018
Time: 11:15 – 1:45 PM MT
Dixon Johns’s presentation will highlight the work led by collaborator Dr. Rowe and his team at the University of Alabama at Birmingham investigating the ability of PAAG to reduce respiratory biofilm integrity.
Presenter: Bryan Garcia, M.D.
Title: Poly Acetyl-Arginyl Glucosamine Has Anti-Biofilm and Anti-Pseudomonal Effect In-Vitro
Date: Thursday, October 18, 2018
Time: 11:15 – 1:45 PM MT
Dr. Garcia’s presentation will highlight work led by collaborators Drs. Rowe and Swords, both at the University of Alabama at Birmingham. The presentation will focus on the anti-biofilm and anti-pseudomonal properties of PAAG.
Research was funded by the CF Foundation and the National Institutes of Health.
About SNSP113
The company’s lead product, SNSP113, is a first-in-class inhaled glycochemistry-based therapeutic with a broad spectrum mechanism of action intended to target the underlying cascade of events that lead to progressive pulmonary disease or other life-threatening pulmonary conditions, such as nontuberculous Mycobacteria(NTM), Burkholderia cepacia complex (BCC), Pseudomonas aeruginosaor methicillin-resistant Staphylococcus aureus(MRSA). SNSP113 is designed to normalize mucin viscosity and improve mucus transport to increase airway clearance. SNSP113 disrupts the cohesion of bacterial biofilms and interacts with the cell walls of invading bacteria to increase their permeability, reduce their viability and potentiate the efficacy of antibiotics. These actions of SNSP113 lead to a reduction in the inflammatory cascade of neutrophils that can lead to pulmonary damage and fibrosis. Progressive pulmonary disease leads to overwhelming symptoms, impacts quality of life (QoL) and results in debilitating progressive lung decline. Synspira is expected to initiate SNSP113 Phase 2 trials in 2019.
About Cystic Fibrosis
Cystic fibrosis (CF) is a progressive genetic disease that causes airway obstruction, persistent lung infections and chronic inflammation of pulmonary tissue leading to permanent lung damage and ultimately resulting in respiratory failure. CF is characterized by the accumulation of thick, sticky mucus in the lungs and clogged airways which impede breathing. Bacteria are not easily cleared and create protective biofilms that are difficult for antibiotics to penetrate and often lead to the emergence of multi-drug resistant bacteria. More than 30,000 people in the United States, and a similar number in Europe, live with cystic fibrosis.